

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **October 1, 2023** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the October 1, 2023 Updates for complete listings of products available by step therapy/special authorization, changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortages of Magnesium-Odan 100 mg/mL Oral Solution (NPN 80004109) manufactured by Odan Laboratories Ltd. and Rougier Magnesium 100 mg/mL Oral Solution (NPN 00026697) manufactured by Teva Canada Limited, Jamp-Magnesium 100 mg/mL Oral Solution (NPN 80009357) manufactured by Jamp Pharma Corporation was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortages for Magnesium-Odan 100 mg/mL Oral Solution (NPN 80004109) and Rougier Magnesium 100 mg/mL Oral Solution (NPN 00026697) have been resolved.

Jamp-Magnesium 100 mg/mL Oral Solution (NPN 80009357) will no longer be considered a temporary benefit for the *ADBL* **after October 11, 2023**. The above grouping was removed from the Critical Supply Product List **September 12, 2023**.

Due to the shortages of Admelog Pen 100 unit/mL Injection (DIN 02469871), Admelog 100 unit/mL Injection Cartridge (DIN 02469898) and Admelog 100 unit/mL Injection (DIN 02469901) manufactured by Sanofi – Aventis, Humalog 100 unit/mL Injection (DIN 02229704), Humalog 100 unit/mL Injection Cartridge (DIN 02229705) and Humalog 100 unit/mL Injection Kwikpen (DIN 02403412) manufactured by Eli Lilly Canada Inc. were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortages for Admelog Pen 100 unit/mL Injection (DIN 02469871), Admelog 100 unit/mL Injection Cartridge (DIN 02469898) and Admelog 100 unit/mL Injection (DIN 02469901) have been resolved.

Humalog 100 unit/mL Injection (DIN 02229704), Humalog 100 unit/mL Injection Cartridge (DIN 02229705) and Humalog 100 unit/mL Injection Kwikpen (DIN 02403412) will no longer be considered temporary benefits for the *ADBL* **after October 19, 2023**. The above grouping was removed from the Critical Supply Product List **September 18, 2023**.

continued next page

PHARMACY BENEFACT

continued from previous page

Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortage for pms-Diclofenac-Misoprostol 75 mg/200 mcg Enteric-Coated Tablet (DIN 02413477) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 12, 2023**. The following grouping was removed from the Critical Supply Product List **September 12, 2023**.

DICLOFENAC SODIUM / MISOPROSTOL

75 MG / 200 MG ENTERIC-COATED TABLET

00002341697	GD-DICLOFENAC / MISOPROSTOL 75	GMD	\$ 0.4286
00002413477	PMS-DICLOFENAC-MISOPROSTOL	PMS	\$ 0.4286
00002229837	ARTHROTEC-75	PFI	\$ 0.9655

Alberta Blue Cross has confirmed that the shortage for Sandoz Sitagliptin-Metformin 50 mg/850 mg Tablet (DIN 02503964) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 23, 2023**. The following grouping was removed from the Critical Supply Product List **September 22, 2023**.

SITAGLIPTIN / METFORMIN HCL

50 MG / 850 MG TABLET

00002503964	SANDOZ SITAGLIPTIN-METFORMIN	SDZ	\$ 0.8893
00002333864	JANUMET	MFC	\$ 1.7465

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Thiamiject 100 mg/mL Injection (DIN 02193221) manufactured by Omega Laboratories Limited, Vitamin B1 100 mg/mL Injection USP (DIN 00816078) manufactured by Sandoz Canada Inc. will be considered a temporary benefit for the ADBL. This grouping was added to the Critical Supply Product List **September 19, 2023**.

As of **September 19, 2023**, all claims for **Vitamin B1 100 mg/mL Injection USP (DIN 00816078)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

